Changeflow GovPing Pharma & Drug Safety Markers, Conjugates, Compositions and Methods f...
Routine Rule Added Final

Markers, Conjugates, Compositions and Methods for Hypoxia Imaging, Mapping, and Therapy

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO granted patent US12600742B2 to WWIKY Biosciences Inc. on April 14, 2026. The patent covers markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy using bio-reductively activated compounds with click chemistry. Inventors include Piyush Kumar, Hassan Elsaidi, Leonard Irving Wiebe, and Michael Weinfeld. The patent includes 5 claims.

What changed

USPTO issued patent grant US12600742B2 to WWIKY Biosciences Inc. for hypoxia imaging technology. The patent covers bio-reductively activated compounds with nitroimidazoles, benzotriazene dioxides, triazoles, and benzoquinones, combined with linker arms and click chemistry for medical imaging applications including PET/SPECT and fluorescent reporting.

For biotech and pharmaceutical companies developing hypoxia-targeted imaging agents or therapeutics, this patent establishes intellectual property boundaries that may require licensing or design-around strategies. Researchers in this space should conduct freedom-to-operate analyses before commercializing related products.

What to do next

  1. Monitor patent portfolio for infringement
  2. Review licensing opportunities

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy

Grant US12600742B2 Kind: B2 Apr 14, 2026

Assignee

WWIKY Biosciences Inc.

Inventors

Piyush Kumar, Hassan Elsaidi, Leonard Irving Wiebe, Michael Weinfeld

Abstract

Described herein are markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy. A compound comprising bio-reductively activated (BA) arm, linker arm and a mapping click wherein BA contains one for more of substituted or unsubstituted 2/4/5-substituted nitroimidazoles, or substituted benzotriazene-1,4-dioxides, or substituted 1,2,3/1,2,4-triazoles, or substituted 1,4-benzoquinones, or a combination of two homo-or hetero BA moieties, wherein linker arm contains C1-16 alkane, alkene, alkyne, alicyclic or aromatic linkers with or without hetero atoms as in ethers, amine, esters, acid, amides, 5 and 6 membered sugar sings with the substitution as described above, both monosaccharides and disaccharides, wherein mapping click contains one of substituted or unsubstituted —N3-, CN, SCN, substituted alkynes for click chemistry. Said compound undergoes in situ click reaction after its distribution in cells or tissues to link to a reporting group which may be unchelated or chelated with a metal-radioactive or non-radioactive-, or a radiohalogen for PET/SPECT, or a dye for fluorescent/optical reporting group, thus accomplishing hypoxia imaging.

CPC Classifications

C07H 15/26 C07D 245/08 C07D 403/12 C07D 405/14 C07D 405/04 A61K 51/0453 A61K 51/0461 A61K 51/0497

Filing Date

2018-09-19

Application No.

16648338

Claims

5

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600742B2

Who this affects

Applies to
Pharmaceutical companies Medical device makers Healthcare providers
Industry sector
3254.1 Biotechnology
Activity scope
Patent prosecution IP licensing Biomedical research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!